- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma
September 15th 2024, 4:29pm
Pembrolizumab continued to demonstrate improved survival vs ipilimumab in unresectable stage III or IV melanoma.
Nivolumab Alone, With Ipilimumab Demonstrate Sustained 10-Year Survival Benefit in Advanced Melanoma
September 15th 2024, 4:18pm
The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.
Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial
September 15th 2024, 4:13pm
Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.
Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC
September 15th 2024, 3:34pm
Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.
Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC
September 15th 2024, 2:49pm
Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.
FOLFIRI Plus Encorafenib and Cetuximab Is Active in BRAF V600E–Mutant mCRC
September 15th 2024, 1:27pm
Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.
Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC
September 14th 2024, 10:20pm
The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.
TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC
September 14th 2024, 10:10pm
Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.
Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC
September 14th 2024, 8:00pm
The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.
Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC
September 14th 2024, 7:50pm
Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.
Zipalertinib Demonstrates Safety, Disease Control in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024, 7:41pm
Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLC
September 14th 2024, 7:15pm
Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.
Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer
September 14th 2024, 7:06pm
Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.
TILs May Prognosticate Survival Benefit With Treatment De-escalation in Early HER2+ Breast Cancer
September 14th 2024, 7:00pm
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
KEYNOTE-A18 Data Support Pembrolizumab Plus Chemoradiotherapy as New SOC in High-Risk Locally Advanced Cervical Cancer
September 14th 2024, 6:32pm
Pembrolizumab plus chemoradiotherapy improved survival in previously untreated, high-risk locally advanced cervical cancer.
Encorafenib/Binimetinib Exhibits Anti-Tumor Activity in Untreated BRAF-Mutant Advanced NSCLC
September 14th 2024, 6:14pm
The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.
Neoadjuvant Dato-DXd Plus Durvalumab Shows Variable pCR Rates in Stage II/III Breast Cancer
September 14th 2024, 5:47pm
Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.
Pembrolizumab Improves Survival for Gastric/GEJ Adenocarcinoma
September 14th 2024, 5:45pm
Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.
Low-Dose Pembrolizumab May Prove Equal Efficacy as a Standard Dose for Stage IV NSCLC
September 14th 2024, 5:19pm
A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.
Frontline Zanidatamab Plus Chemo ± Bevacizumab Is Safe, Active in HER2+ mCRC
September 14th 2024, 4:59pm
Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.